Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment
Information source: Universidad Autonoma de Nuevo Leon
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bursitis
Intervention: EXPERIMENTAL (Drug); PLACEBO (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Universidad Autonoma de Nuevo Leon Official(s) and/or principal investigator(s):
Mario Alberto Garza Elizondo, MD, Study Director, Affiliation: Universidad Autónoma de Nuevo León
Summary
To investigate the safety and efficacy of methylprednisolone infiltration in anserine
bursitis treatment
Clinical Details
Official title: Phase 2 Double-blinded, Placebo-controlled, Clinical Trial for Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: WOMAC score
Secondary outcome: VAS satisfactionImprovement SAFETY
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical diagnosis of anserine bursitis
Exclusion Criteria:
- Intraarticular pathology that reflects pain in the medial part of the knee
Locations and Contacts
Hospital Universitario "José Eleuterio González", Monterrey, Nuevo León 66024, Mexico
Additional Information
Related publications: Alvarez-Nemegyei J, Canoso JJ. Evidence-Based Soft Tissue Rheumatology IV: Anserine Bursitis. J Clin Rheumatol. 2004 Aug;10(4):205-6. Calvo-Alén J, Rua-Figueroa I, Erausquin C. Anserine bursitis treatment: local corticoesteroid injction against NSAID: a prospective study [Spanish]. Rev Esp Reumatol. 1993;20:13-15.
Starting date: September 2009
Last updated: September 17, 2010
|
